High frequencies of general CD8+ T cells in the cHL TME are associated with a better outcome, especially in the advanced-disease group [9,27], whereas worse prognosis is associated with a greater abundance of activated (GrB+ TIA1+) CD8+ T cells [5,7,14,36]. This evidence concerns the gene CD8A and classic Hodgkin lymphoma.